Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36033 THERAVANCE BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Cayman Islands 98 ...

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2021 Earnings Conference Call November 3, 2021 5:00 PM ET Company Participants Gail Cohen - Vice President, Corporate Communications Rick Winningham - Chief Executive Officer Rhonda Farnum - Senior Vice President, Commercial and Medical Affairs Rick Graham - Senior Vice President, Research and Development Andrew Hindman - Chief Financial Officer Conference Call Participants Geoffrey Porges - SVB Leerink Marc Frahm - Cowen & Company Liisa Bayko - Evercore ISI Vikra ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36033 THERAVANCE BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Cayman Islands 98-1226 ...

| --- | --- | |---------------------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | Second Quarter 2021 | | | Financial Results and Business Update | | | August 3, 2021 | | THERAVANCE BIOPHARMA®, THERAVANCE®, the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. © 2021 Theravance Bio ...

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2021 Earnings Conference Call August 3, 2021 5:00 PM ET Company Participants Gail Cohen - Vice President, Corporate Communications Rick Winningham - Chief Executive Officer Rick Graham - Senior Vice President, Development Frank Pasqualone - Chief Business Officer Andrew Hindman - CFO Conference Call Participants Anna Baran - SVB Leerink Marc Frahm - Cowen & Company Liisa Bayko - Evercore ISI Douglas Tsao - H.C. Wainright Anupam Rama - JPMorgan Vikram Purohit - Mor ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36033 THERAVANCE BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Cayman Islands 98-122 ...

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2021 Earnings Conference Call May 4, 2021 5:00 PM ET Company Participants Gail Cohen - Vice President, Corporate Communications Rick Winningham - Chief Executive Officer Rick Graham - Senior Vice President, Development Frank Pasqualone - Chief Business Officer Andrew Hindman - Chief Financial Officer Conference Call Participants Liisa Bayko - Evercore ISI Marc Frahm - Cowen Geoffrey Porges - SVB Leerink Anupam Rama - JPMorgan Douglas Tsao - H.C. Wainwright Vikram ...

| --- | --- | |-------------------------------------------------------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | Fourth Quarter and Full Year 2020 Financial Results and Business Update | | | February 23, 2021 | | THERAVANCE BIOPHARMA®, THERAVANCE®, the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the p ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36033 THERAVANCE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Cayman Islands 98-1226628 (Sta ...

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2020 Earnings Conference Call February 23, 2021 5:00 PM ET Company Participants Gail Cohen - VP, Corporate Communications and IR Rick Winningham - CEO Frank Pasqualone - Chief Commercial Operations Officer Brett Haumann - Chief Medical Officer Andrew Hindman - CFO Conference Call Participants Geoffrey Porges - SVB Leerink Marc Frahm - Cowen Douglas Tsao - H.C. Wainwright Liisa Bayko - Evercore ISI Anupam Rama - JPMorgan Vikram Purohit - Morgan Stanley Brian Skorn ...